Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis

Canadian Journal of Cardiology

Volumn 31, Issue 6, 2015, Pages 792-799

  Miller, Robert J H ^a   Howlett, Jonathan G ^a   Exner, Derek V ^a   Campbell, Patricia M ^a   Grant, Andrew D M ^a   Wilton, Stephen B ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ATTRIBUTABLE RISK; CARDIAC RESYNCHRONIZATION THERAPY; CAUSE OF DEATH; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HEART PACING; MALE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC PACING, ARTIFICIAL; CARDIAC RESYNCHRONIZATION THERAPY; CAUSE OF DEATH; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84929718487     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.12.031     Document Type: Review

References (48)

1. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels 1994, New York Heart Association Criteria Committee, Little, Brown, Boston. 9th Ed.
2. Muntwyler J., Abetel G., Gruner C., Follath F. One-year mortality among unselected outpatients with heart failure. Eur Heart J 2002, 23:1861-1866.
3. Rostagno C., Galanti G., Comeglio M., et al. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail 2000, 2:273-280.
4. Bennett J.A., Riegel B., Bittner V., Nichols J. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 2002, 31:262-270.
5. Goldman L., Hashimoto B., Cook E.F., Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale. Circulation 1981, 64:1227-1234.
6. Phelan D., Thavendiranathan P., Collier P., Marwick T.H. Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials. Heart 2012, 98:1693-1700.
7. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.
8. Food and Drug Administration Center for Drug Evaluation and Research. Available at: . Accessed April 12, 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
9. Higgins J.P., Altman D.G., Gøtzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
10. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival study. NEngl J Med 1987, 316:1429-1435. The CONSENSUS Trial Study Group.
11. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. NEngl J Med 1991, 325:293-302. The SOLVD Investigators.
12. Yusuf S., Nicklas J.M., Timmis G., et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. NEngl J Med 1992, 327:685-691.
13. Keren G., Pardes A., Eschar Y., et al. One-year clinical and echocardiographic follow-up of patients with congestive cardiomyopathy treated with captopril compared to placebo. Isr J Med Sci 1994, 30:90-98.
14. Arandomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994, 90:1765-1773.
15. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 1995, 92:212-218.
16. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999, 353:9-13.
17. Effect of metoprolol cr/xl in chronic heart failure: Metoprolol cr/xl randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007.
18. Atrial of the beta-blocker bucindolol in patients with advanced chronic heart failure. NEngl J Med 2001, 344:1659-1667. Beta-Blocker Evaluation of Survival Trial Investigators.
19. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. NEngl J Med 2001, 344:1651-1658.
20. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. NEngl J Med 1999, 341:709-717.
21. Boccanelli A., Mureddu G.F., Cacciatore G., et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF Study): final results. Eur J Heart Fail 2009, 11:68-76.
22. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEngl J Med 2011, 364:11-21.
23. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. NEngl J Med 1996, 335:1933-1940.
24. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346:877-883.
25. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. NEngl J Med 2004, 350:2140-2150.
26. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. NEngl J Med 2004, 350:2151-2158.
27. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. NEngl J Med 2005, 352:225-237.
28. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. NEngl J Med 2002, 346:1845-1853.
29. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD trial. JAMA 2003, 289:2685-2694.
30. Abraham W.T., Young J.B., Leon A.R., et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation 2004, 110:2864-2868.
31. Cleland J.G., Daubert J.C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. NEngl J Med 2005, 352:1539-1549.
32. Linde C., Abraham W.T., Gold M.R., et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. JAm Coll Cardiol 2008, 52:1834-1843.
33. Moss A.J., Hall W.J., Cannom D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. NEngl J Med 2009, 361:1329-1338.
34. Tang A.S., Wells G.A., Talajic M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. NEngl J Med 2010, 363:2385-2395.
35. Cohn J.N., Tognoni G. Arandomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl J Med 2001, 345:1667-1675. Valsartan Heart Failure Trial Investigators.
36. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
37. Hamroff G., Katz S.D., Mancini D., et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999, 99:990-992.
38. Haynes R.B., Sackett D.L., Guyatt G.H., Tugwell P. Chapter 6: The principles behind the tactics of performing therapeutic trials. Clinical Epidemiology: How to Do Clinical Practice Research 2006, 173-243. Lippincott, Williams & Wilkins.
39. Ørn S., Dickstein K. How do heart failure patients die?. Eur Heart J Suppl 2002, 4:D59-D65.
40. Liu P., Arnold M., Belenkie I., et al. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure. Can J Cardiol 2001, 17(suppl E):5E-25E.
41. McKelvie R.S., Moe G.W., Cheung A., et al. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011, 27:319-338.
42. Hernandez A.F., Hammill B.G., O'Connor C.M., et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. JAm Coll Cardiol 2009, 53:184-192.
43. Packer D.L., Prutkin J.M., Hellkamp A.S., et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the Sudden Cardiac Death in Heart Failure trial. Circulation 2009, 120:2170-2176.
44. Yancy C.W., Jessup M., Bozkurt B., et al. 2013 ACCF/AHA guideline for the management of heart failure. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. JAm Coll Cardiol 2013, 62:e147-e239.
45. Covey J. Ameta-analysis of the effects of presenting treatment benefits in different formats. Med Decis Making 2007, 27:638-654.
46. Stacey D., Bennett C.L., Barry M.J., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011, CD001431.
47. Rywik S.L., Wagrowska H., Broda G., et al. Heart failure in patients seeking medical help at outpatients clinics. Part I. General characteristics. Eur J Heart Fail 2000, 2:413-421.
48. Arnold J.M., Ignaszewski A., Kaan A., et al. Cardiovascular co-morbidities and five year survival in a large contemporary outpatient cohort of patients with chronic heart failure. JAm Coll Cardiol 2012, 59:E1051.